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Cancer is the second-most common 
cause of mortality and morbidity in 
developed countries. In addition to its 
direct costs in terms of quality-adjusted 
life years lost, it also contributes to the 
economic costs of disease as cancer 
patients often reduce their working 
hours or cease employment completely.
Recent decades have seen increased 
innovation in the treatment of many 
types of cancer. Pharmaceutical 
innovation has resulted in new 
chemotherapy drugs—often used in 
combinations—that are more effective 
in targeting tumors while reducing 
harm for healthy body tissue. In 
addition, new surgical techniques 
alleviate side effects and lead to shorter 
recovery times.
I investigate whether medical 
innovation in the treatment of breast 
and prostate cancers, which are the 
most common types of cancers among 
women and men, respectively, also 
lead to a reduction in the economic 
costs of cancer. Specifically, I use large 
administrative databases from Canada 
to estimate how the employment effect 
of a cancer diagnosis is moderated 
by medical innovation. I employ a 
difference-in-differences strategy 
combined with matching to estimate 
the causal effect of a cancer diagnosis 
and how it changes with medical 
innovation.
Confirming previous research, I first 
find that a cancer diagnosis reduces 
employment by 2 to 4 percentage 
points. Second, the cumulative 
medical innovation that improved 
cancer treatment during the 1990s and 
2000s led to a decrease in the negative 
employment effects of prostate and 
breast cancer by about 65 percent. 
Hence, the approval of additional drugs 
and the introduction of other medical 
technologies over this time period are 
associated with a substantial reduction 
in the economic costs of cancer. 
Finally, I consider the employment 
effects of cancer diagnoses and 
medical innovation by cancer patients’ 
education. I find that the benefits of 
innovation are limited to individuals 
with postsecondary education, while 
cancer patients with lower levels of 
education experience a larger decline in 
employment.
From a policy perspective, these 
results suggest that innovations in 
cancer treatment may provide benefits 
beyond direct medical effects. As 
innovative cancer treatments can be 
very expensive, it is therefore important 
to account for economic benefits such 
as smaller reductions in labor income 
and, as a result, tax revenue when 
determining whether the benefits 
of a new treatment option outweigh 
its cost. The heterogenous effects 
likely to be benefits throughout the 
region.
However, there are several 
shortcomings of the migration chain 
mechanism, particularly in the 
lowest-cost and most-rent-burdened 
neighborhoods. Census tracts in the 
bottom fifth of household income 
and the top fifth of rent burden 
(rent as a share of income) have 
an average vacancy rate of 12.8 
percent, compared to 8.1 percent 
in the rest of my sample. Given 
that rents are generally already 
low in such neighborhoods, this 
suggests that reducing demand 
through the migration chain 
mechanism is unlikely to lower 
costs further, perhaps because rents 
have reached the minimum cost of 
housing. Moreover, there may also 
be important amenity effects if the 
migration chain reduces population 
in these areas, such as reduced retail 
options, school closures, or increased 
crime. Vouchers or policies that 
lower the cost of housing (such as 
reductions in property tax or utility 
rates) may be necessary to lower 
prices in this segment of the market.
In addition, while I focus on 
regional implications, new buildings 
could have very different effects on 
their immediate area, where they 
may change amenities or household 
composition in ways that affect prices. 
There is little existing direct evidence 
on how these factors change following 
new construction, and this could be a 
fruitful area for future research. 
Note
1.  I focus on one metropolitan area 
because there is large variation across 
both race and income in large cities. 
Results are similar for other areas.
Evan Mast is an economist at the Upjohn Institute.
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n Innovations in cancer treatment may alleviate the economic costs of cancer diagno-
ses, such as a decline of labor supply.
n I find that medical innovation reduces the negative employment effect of cancer 
diagnoses by about 65 percent during the study period.
n The economic benefits of medical innovation are limited to cancer patients with 
postsecondary education, raising concerns about equal access to new treatments.
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This article draws on research from an Upjohn Institute 
working paper, which can be found at https://research 
.upjohn.org/up_workingpapers/307.
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before and after the diagnosis and 
allow the employment effects of cancer 
diagnoses and medical innovation to 
vary over time, as it is plausible that 
these effects do not remain constant 
within this time frame.
Results
I find that some breast and 
prostate cancer patients reduce their 
employment after the diagnosis when 
compared to the matched control 
group. Men are 1.8 percentage points 
less likely to be employed after a 
prostate cancer diagnosis, and women 
are 3.9 percentage points less likely 
to be employed after a breast cancer 
diagnosis.
Medical innovation substantially 
reduces the negative employment 
effects of cancer diagnoses. Figure 1 
shows the effect of a prostate cancer 
diagnosis on employment as a function 
of the number of drugs available for the 
treatment of this disease. In 1992 when 
14 drugs were approved, employment 
of prostate cancer patients dropped by a 
few percentage points initially, and the 
decline reached more than 5 percentage 
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by education indicate that the mere 
existence of new medical technology 
may not automatically lead to improved 
economic outcomes, but rather that 
there are barriers to access them.
Background
The most common types of cancers 
are breast and prostate, affecting 
about 26,000 women and 21,000 men, 
respectively, in Canada annually. While 
most cancers affect older individuals, 
a substantial subgroup of breast and 
prostate cancer patients is diagnosed 
during their working age. Because 
cancer treatment is lengthy and can 
cause severe side effects, patients 
undergoing treatment often reduce 
their labor supply or stop working 
completely. These negative labor market 
effects may be alleviated by improved 
treatment options that are more likely 
to cure cancer in a shorter amount of 
time and lead to fewer side effects.
To investigate the effect of cancer 
diagnoses and medical innovation on 
employment, I combine data from 
several sources. First, I identify breast 
and prostate cancer patients from the 
Canadian Cancer Database. Second, 
I use individual tax returns from the 
Longitudinal Worker File to measure 
employment of cancer patients before 
and after their diagnosis, as well as 
employment of individuals who were 
never diagnosed with cancer and who 
serve as a control group. Statistics 
Canada merged these data sets to the 
1991 population census, which contains 
individual characteristics such as 
educational attainment.
Finally, I measure medical 
innovation in two different ways. A 
first, more narrow measure is the 
number of drugs that are approved for 
the treatment of breast and prostate 
cancer. Pharmaceutical innovation is 
important, as chemotherapy is one of 
the main treatment options for cancer. 
Throughout the study period, the 1990s 
and 2000s, several important new drugs 
were approved—the chemotherapy 
drug Trastuzumab for the treatment 
of breast cancer, and triptorelin, a 
luteinizing hormone-releasing hormone 
analogue used to fight prostate cancer.
In addition to chemotherapy, 
surgery and radiation are used as cancer 
treatment. Notable innovations include 
laparoscopic radical prostatectomy, a 
minimally invasive surgical technique, 
and breast-conserving surgery, both 
of which reduce recovery time and 
potential side effects after surgery. To 
broadly capture innovation in these 
areas, I use international patent data. 
From these records, I construct a 
quality-weighted patent index that 
measures the aggregate and cumulative 
innovative activity related to breast and 
prostate cancer treatment.
Before I estimate the effect of cancer 
diagnoses and medical innovation 
on employment, I use a matching 
technique to create a control group 
consisting of individuals without cancer 
that is identical to cancer patients along 
all observed dimensions. I then employ 
a difference-in-differences strategy—I 
compare employment rates of cancer 
patients and the matched control 
group both before and after the cancer 
diagnosis. I consider a five-year window 
SOURCE: Statistics Canada and author’s calculations.
Figure 1  Effect of Prostate Cancer on Employment by Number of Approved Drugs
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points after three years (blue line; I 
show the effects prior to the diagnosis 
to rule out any preexisting trends). In 
contrast, when 27 approved drugs were 
available in 2010, a prostate diagnosis 
reduced employment by only about 1 
percentage point during the first five 
years (red line).
For the employment effects of 
breast cancer diagnoses and the role 
of medical innovation, Figure 2 shows 
a similar pattern. As the number of 
drugs approved for the treatment of 
breast cancer increased from 17 to 39 
between 1992 and 2010, the decline 
in employment following a diagnosis 
became smaller. At the lowest level 
of pharmaceutical innovation, breast 
cancer reduces employment by about 
2.5 percentage points initially and up to 
5 percentage points three years after the 
diagnosis and beyond (blue line). At the 
highest number of drugs available, the 
initial decline in employment is similar, 
but after three years, the employment 
effect becomes indistinguishable from 0 
(red line).
When repeating this exercise with 
the quality-weighted patent index 
instead of the number of approved 
drugs, I find similar patterns (not 
shown). Hence, I provide evidence 
suggesting that medical innovation in 
the form of new drugs and medical 
technology alleviates the economic 
costs of breast and prostate cancer 
diagnoses. On average, medical 
innovation reduced the decline in 
employment among cancer patients 
by about 65 percent between 1992 
and 2010. These effects imply that the 
annual average earnings losses due to 
a prostate and breast cancer diagnosis 
are $1,100 and $600, respectively, lower 
than they would have been without 
medical innovation. Therefore, a 
substantial economic benefit arises 
from these innovations, in addition to 
any resulting reductions in mortality 
and morbidity.
To better understand how education 
interacts with medical innovation in the 
employment of cancer patients, I split 
the sample by educational attainment 
into individuals without a high school 
degree, those who have graduated 
from high school but have no further 
education, and those with at least some 
postsecondary education. Among these 
subsamples, I only observe a mitigating 
impact of medical innovation on the 
negative employment effect of cancer 
diagnoses for breast and prostate cancer 
patients with postsecondary education. 
This is despite the fact that individuals 
with lower levels of education reduce 
their employment by more than those 
with postsecondary education.
Although my data do not allow 
me to determine the underlying 
mechanism, there are several potential 
explanations for the observed 
heterogeneity by education. First, 
higher levels of education may help 
cancer patients identify medical 
providers who use innovative 
treatments. Second, education may 
enable cancer patients to obtain 
information on treatment options and 
demand that their medical providers 
use up-to-date treatments. Third, 
adherence to complex treatment 
regimens could be facilitated by higher 
educational attainment. Finally, it is 
possible that cancer patients with low 
education levels work in physically 
more demanding jobs where it is 
more difficult to undergo a modern 
high-intensity cancer treatment while 
remaining employed. Independent of 
the actual mechanism, the fact that only 
highly educated individuals profit from 
innovative cancer treatments suggests 
that the economic benefits of medical 
innovation are distributed unequally.
Implications
The empirical findings have several 
important implications. First, they 
highlight the importance of accounting 
for indirect (economic) benefits in a 
cost-benefit analysis of new medical 
technologies. Although the benefits 
in terms of lower earnings losses are 
smaller by an order of magnitude than 
the annual cost of an intensive cancer 
treatment, which can exceed $100,000, 
the benefits are substantial. Therefore, 
they should be considered in addition 
to potential improvements in terms of 
mortality and morbidity.
Second, these findings suggest 
potential policies that can alleviate 
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Figure 2  Effect of Breast Cancer on Employment by Number of Approved Drugs
SOURCE: Statistics Canada and author’s calculations.
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The authors examine detailed administrative 
data from three states—Georgia, Missouri, and 
South Carolina—and find that state rules and 
regulations often deter eligible low-income 
workers from receiving benefits while presenting 
hurdles for those who are already eligible to 
recertify for 
benefits. The 
effects of various 
certification and 
recertification 
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but the authors 
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impacts of the 
relaxed provisions 
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easier for able-bodied adults without dependents 
to receive food stamp benefits. They also 
critique a variety of policy proposals to alter the 
program, and offer several proposals for making 
the program less onerous for working families 
and individuals while addressing valid program 
concerns.
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the economic costs of disease. It is of 
particular concern that cancer patients 
experience lower employment rates and 
hence earnings losses in addition to the 
pain and suffering caused by their disease. 
Thus, encouraging and subsidizing medical 
innovation may have the dual benefit of 
mitigating both the medical and economic 
consequences of cancer and other diseases. 
Investments in research that lead to new 
treatment options may very well have a 
positive return if the resulting innovation 
has economic in addition to medical 
benefits.
Last, the fact that medical innovation 
does not yield economic gains for cancer 
patients with lower levels of education 
raises concerns about unequal access to 
up-to-date treatment options. Especially 
when medical research is publicly 
financed, it is reasonable to expect that 
resulting innovation should benefit cancer 
patients irrespective of their demographic 
or socioeconomic background. Moreover, 
in the case of the employment effects 
of cancer diagnoses, individuals with 
the lowest levels of education suffer 
the highest economic cost. Therefore, 
policymakers may need to ensure that 
new and innovative treatment options are 
accessible to all patients who would benefit 
from them, such as through information 
campaigns targeted at these individuals. 
In addition, medical education could 
increasingly emphasize the importance of 
accounting for patients’ socioeconomic 
backgrounds in choosing appropriate 
cancer treatments.
In sum, these findings highlight the 
importance of considering interactions 
between labor markets and health care and 
point out several policy options aimed at 
reducing the economic burden of disease.
This article draws on research from an Upjohn Institute working 
paper, which can be found at https://research.upjohn.org/
up_workingpapers/306.
R. Vincent Pohl is an assistant professor at the University of 
Georgia.
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to respond to the 
needs of many of the victims of the recession. 
But little has been known about how the two 
programs interact. The chapters in this book show 
that, indeed, each program has considerable 
effects on the other and that policies governing 
them could be improved. Following chapters 
that detail the SNAP and UI programs along with 
existing research on their interaction, the editors 
use administrative data from six states to reveal 
how the programs interact and how they can be 
altered to work more effectively.
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